glp-1 agonists cancer risk of pancreatic associated with receptor agonist therapy Long-term cancer risk in users

Several additional GLP-1 receptor agonists also display neuroprotective properties in preclinical AD models

The research spans regions including Asia-Pacific, Western Europe, and North America, covering countries such as the USA, UK, China, and Germany

Effective diets ultimately work by reducing caloric intake, limiting the content that sustains excess body fat

Each GLP-1RA has explicit indications and contraindications for weight loss [Reference Pratley, Kang, Trautmann, Hompesch, Han and Stewart49]

Therefore, these medications deserve consideration as primary cardiovascular drugs rather than merely adjunctive diabetes therapies